Pharmacology, biochemistry, and behavior
June 30, 2026
Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.
Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...
Journal of Psychopharmacology
June 28, 2026
Yiğit Özaydın, Buket Canlan Özaydın
Background: Psychedelic microdosing—repeated sub-perceptual doses of lysergic acid diethylamide (LSD) or psilocybin—has attracted scientific interest as a potential mood and cognitive intervention. The evidence base remains methodologically heterogeneous and vulnerable to expectancy bias. Methods: We conducted an umbrella review with narrative synthesis following Joanna Briggs Institute...
Journal of Psychoactive Drugs
June 19, 2026
Carla J. Berg, Darcey M. Mccready, Cassidy R Loparco et al.
= 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to: (1) past-year psychedelic use; and (2) among those reporting lifetime use: (a) lifetime microdosing and (b) use motives. Lifetime and past-year psychedelic use were 27.7% and 11.9% (commonly...
Journal of Advances in Developmental Research
June 18, 2026
Eric P. Rubenstein
Microdosing and related low-dose psychoactive practices have become increasingly visible in discussions of mental health, cognition, creativity, emotional regulation, pain, sleep, spirituality, and psychological flexibility. However, the term microdosing is often used as if it referred to a single pharmacological phenomenon. More precisely, it describes a low-dose application pattern used...
Frontiers in Pharmacology
June 3, 2026
Burton J. Tabaac, Robin Carhart-Harris, Teresa Yung
Background: Traumatic brain injury (TBI) can result in prolonged post-concussive syndrome and chronic hypoxic-ischemic brain injury (HIBI) sequelae remains therapeutically challenging with the persistence of significant neurological and cognitive impairments. While conventional treatments often provide limited relief, emerging research explores alternative therapeutic interventions, including...
Rand health quarterly
June 1, 2026
Michelle Priest, Beau Kilmer, Ben Senator et al.
An increasing number of U.S. states are implementing or considering alternative policies to the prohibition of some psychedelic substances for nonclinical purposes. The authors present new data and analysis to inform these discussions with survey results on the use of 11 psychedelic substances and detailed information about the prevalence of microdosing (i.e., taking a fraction of a full dose,...